Lopid
(Gemfibrozil)ApprovedSmall molecule
PfizerGemfibrozil is used to lower cholesterol and triglycerides (a type of fat) in the blood to help reduce the risk of heart disease and stroke.[2] Lopid is currently approved and in use across 10 indications[4].[1]
Lopid is one of 295 small molecule programs targeting Familial Hyperlipidemia. It is currently in Approved.
10
Indications
33
Total Trials
0
Active Trials
294
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Lopid
PfizerApproved
Retatrutide
Eli LillyPhase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
Elecoglipron
AstraZenecaPhase 3
GZR4
GGan and Lee Pharmaceuticals, USA
Phase 3
Imeglimin
PPoxel SA
Phase 3
TG103
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cipro
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Interaction8 trials
Show 5 more trials
Treatment2 trials
Single Dose2 trials
Drug Interactions2 trials
18 more indications
Heart Disease1 trial
Adult Subject1 trial
Empagliflozin1 trial
Alzheimer disease1 trial
Solid Tumors1 trial
Drug1 trial
Lip1 trial
Concentration1 trial
CAR1 trial
Atherosclerotic Plaque1 trial
Medication1 trial
Parkinson disease1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LOPID
NDA NDA018422
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lopid drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Gemfibrozil. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]